

amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, NCI Experimental Therapeutics Program (NExT) Cycle 2.

*Date:* January 13, 2010.

*Time:* 8:30 a.m.–4:30 p.m.

*Agenda:* To evaluate the NCI Experimental Therapeutics Program Portfolio.

*Place:* National Institutes of Health, Building 31A—Conference Room 8A28, 31 Center Drive, Bethesda, MD 20817.

*Contact Person:* Dr. Barbara Mroczkowski, Executive Secretary, NCI Experimental Therapeutics Program, National Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda, MD 20892. (301) 496-4291. [mroczkowskib@mail.nih.gov](mailto:mroczkowskib@mail.nih.gov).

This notice is being published less than 30 days prior to the meeting due to scheduling conflicts.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: December 22, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9-31012 Filed 12-29-09; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, NCI Discovery and Development P01.

*Date:* February 2–3, 2010.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Sergei Radaev, PhD., Scientific Review Officer, Resources And Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8113, Rockville, MD 20852, 301-435-5655, [sradaev@mail.nih.gov](mailto:sradaev@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Epidemiology, Prevention, Control & Population Sciences.

*Date:* February 9–11, 2010.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

*Contact Person:* Wlodek Lopaczynski, M.D., PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8131, Bethesda, MD 20892, 301-594-1402, [lopacw@mail.nih.gov](mailto:lopacw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Molecular Oncology—Basic, Translational, and Clinical Studies.

*Date:* February 9–11, 2010.

*Time:* 5 p.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD.

*Contact Person:* David G. Ransom, PhD, Scientific Review Officer, Research Programs

Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Rm. 8133, Bethesda, MD 20892-8328, 301-451-4757, [david.ransom@nih.gov](mailto:david.ransom@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, SPORE in Gynecologic, Breast, and Skin Cancers.

*Date:* February 17–19, 2010.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, Bethesda, MD.

*Contact Person:* Caron A. Lyman, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd, Room 8119, Bethesda, MD 20892-8328, 301-451-4761, [lymanc@mail.nih.gov](mailto:lymanc@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel, SPORE in Brain, Leukemia, Myeloma, Sarcoma, Esophageal, GI, HN, and Pancreatic Cancers.

*Date:* February 17–19, 2010.

*Time:* 8 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Shamala K. Srinivas, PhD., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8123, Bethesda, MD 20892, 301-594-1224, [ss537t@nih.gov](mailto:ss537t@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: December 21, 2009.

**Jennifer Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9-30923 Filed 12-29-09; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2009-N-0664]

#### Advisory Committees; Tentative Schedule of Meetings for 2010

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory

committees for 2010. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. In its final report, one of the IOM's recommendations was for the agency to publish an annual tentative schedule of its meetings in the **Federal Register**. This publication implements the IOM's recommendation.

**FOR FURTHER INFORMATION CONTACT:**

Teresa L. Hays, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

**SUPPLEMENTARY INFORMATION:** The IOM, at the request of the Commissioner,

undertook a study of the use of the FDA's advisory committees. In its final report in 1992, one of the IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Because the schedule is tentative amendments to this notice will not be published in the **Federal Register**. However, changes to

the schedule will be posted on the FDA advisory committees' Internet site located at <http://www.fda.gov/AdvisoryCommittees/default.htm>. FDA will continue to publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 2010. You may also obtain up-to-date information by calling the Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area) and use the appropriate Information Line Code for the committee in which you are interested.

Committee Name	Tentative Date of Meeting(s)	Advisory Committee 10-Digit Information Line Code
<b>OFFICE OF THE COMMISSIONER</b>		
Pediatric Advisory Committee	March 22, June 21–22, September 20–21, December 6–7	8732310001
Risk Communication Advisory Committee	February 25–26, May 6–7, August 19–20, November 8–9	8732112560
Science Board to the Food and Drug Administration	February 22, May 17, August 16, November 15	3014512603
<b>CENTER FOR BIOLOGICS EVALUATION AND RESEARCH</b>		
Allergenic Products Advisory Committee	April 30, October 26	3014512388
Blood Products Advisory Committee	April 12–13, July 26–27, November 18–19	3014519516
Cellular, Tissue and Gene Therapies Advisory Committee	To be announced	3014512389
Transmissible Spongiform Encephalopathies Advisory Committee	To be announced	3014512392
Vaccines and Related Biological Products Advisory Committee	February 22, May 19–20, September 15–16, November 17–18	3014512391
<b>CENTER FOR DRUG EVALUATION AND RESEARCH</b>		
Anesthetic and Life Support Drugs Advisory Committee	January 28, April 22, April 23	3014512529
Anti Infective Drugs Advisory Committee	August and October dates To be announced	3014512530
Antiviral Drugs Advisory Committee	To be announced	3014512531
Arthritis Advisory Committee	May dates To be announced	3014512532
Cardiovascular and Renal Drugs Advisory Committee	January 11, March 1, April dates to be announced, July 28, July 29, December 8, December 9	3014512533
Dermatologic and Ophthalmic Drugs Advisory Committee	To be announced	3014512534
Drug Safety and Risk Management Advisory Committee	To be announced	3014512535
Endocrinologic and Metabolic Drugs Advisory Committee	January 12, January 13, February 24, May 26–27	3014512536
Gastrointestinal Drugs Advisory Committee	February 23, November dates to be announced	3014512538
Nonprescription Drugs Advisory Committee	To be announced	3014512541
Oncologic Drugs Advisory Committee	February 10, May 4, May 5, July 20, July 21, September 1, September 2, December 1, December 2	3014512542

Committee Name	Tentative Date of Meeting(s)	Advisory Committee 10-Digit Information Line Code
Peripheral and Central Nervous System Drugs Advisory Committee	March 23, March 24, June dates to be announced	3014512543
Pharmaceutical Science and Clinical Pharmacology, Advisory Committee	March 17	3014512539
Psychopharmacologic Drugs Advisory Committee	To be announced	3014512544
Pulmonary Allergy Drugs Advisory Committee	March 9, March 10, April dates to be announced	3014512545
Reproductive Health Drugs, Advisory Committee	May dates to be announced	3014512537

## CENTER FOR DEVICES AND RADIOLOGICAL HEALTH

Device Good Manufacturing Practice Advisory Committee	July 22, September 16	3014512398
Medical Devices Advisory Committee (Comprised of 18 Panels)		
Anesthesiology and Respiratory Therapy Devices Panel	April 30, June 23, September 15, November 10	3014512624
Circulatory System Devices Panel	February 25, May 27, September 23, December 8–9	3014512625
Clinical Chemistry and Clinical Toxicology Devices Panel	March 17–18, June 16–17, October 20–21	3014512514
Dental Products Panel	March 23, April 13, May 11, July 13, September 14	3014512518
Ear, Nose, and Throat Devices Panel	February 24, May 19, August 25, November 3–4	3014512522
Gastroenterology-Urology Devices Panel	March 11–12, June 17–18, September 9–10, December 2–3	3014512523
General and Plastic Surgery Devices Panel	February 4–5, May 20–21, August 12–13, November 4–5	3014512519
General Hospital and Personal Use Devices Panel	March 5, July 28–29, November 17–18	3014512520
Hematology and Pathology Devices Panel	January 21–22, April 22–23, July 8–9, October 21–22	3014512515
Immunology Devices Panel	April 26, September 15, December 6	3014512516
Medical Devices Dispute Resolution Panel	Meetings occur as needed	3014510232
Microbiology Devices Panel	March 19, September 23	3014512517
Molecular and Clinical Genetics Panel	April 15, October 5–6	3014510231
Neurological Devices Panel	March 11–12, May 13–4, July 8–9, October 7–8, December 9–10	3014512513
Obstetrics and Gynecology Devices Panel	April 22–23, July 15–16, October 21–22, December 16–17	3014512524
Ophthalmic Devices Panel	February 25–26, April 22–23, June 24–25, October 28–29, November 18–19	3014512396
Orthopedic and Rehabilitation Devices Panel	March 23, June 9–10, October 13–14, December 1–2	3014512521
Radiological Devices Panel	April 28, July 21, September 15, November 17	3014512526
National Mammography Quality Assurance Advisory Committee	January 25	3014512397
Technical Electronic Product Radiation Safety Standards Committee	No meeting tentatively scheduled for 2010	3014512399

## CENTER FOR FOOD SAFETY AND APPLIED NUTRITION

Food Advisory Committee	May 20–21	3014510564
-------------------------	-----------	------------

## CENTER FOR VETERINARY MEDICINE

Veterinary Medicine Advisory Committee	March 18–19	3014512548
----------------------------------------	-------------	------------

## NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR)

Committee Name	Tentative Date of Meeting(s)	Advisory Committee 10-Digit Information Line Code
Science Advisory Board to NCTR Center for Tobacco	November 17–18	3014512559
Tobacco Products Scientific Advisory Committee	March, May, July, and November dates to be announced	8732110002

Dated: December 24, 2009.

**David Horowitz,**

*Assistant Commissioner for Policy.*

[FR Doc. E9–30973 Filed 12–29–09; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2009–N–0664]

#### Second Annual Sentinel Initiative Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public workshop.

The Food and Drug Administration (FDA) is announcing the following workshop: Second Annual Sentinel Initiative Public Workshop. This 1-day workshop, organized and hosted by the Engelberg Center for Health Care Reform at Brookings, is supported by a grant from FDA. This workshop is intended to communicate the current status and future vision of active medical product surveillance activities and explore stakeholder perspectives on a broad range of issues. The workshop will feature a series of presentations on recently completed FDA contracts to inform various aspects of the development of the Sentinel System; an update on FDA's ongoing pilot projects in active surveillance of medical product safety; and a discussion of three issues of broad interest: maintaining patient privacy while conducting medical product safety surveillance, developing the Sentinel System as a national resource for medical product safety surveillance for others outside of FDA, and developing a multi-purpose distributed system that can be used to conduct safety surveillance, comparative effectiveness research, product quality assessment and to address other types of public health questions.

**Date and Time:** The workshop will be held on January 11, 2010, from 8:30 a.m. to 4:45 p.m.

**Location:** The workshop will be held at Marriott Metro Center at 775 12th Street NW., Washington, DC 20005.

**Contact:** Kayla Garvin, Center for Drug Evaluation and Research, Bldg. 22, rm. 4339, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20903, 301–796–3755, e-mail:

*Kayla.Garvin@fda.hhs.gov.*

**Registration:** To attend the workshop, please register at <http://tinyurl.com/yce6c3z>. When registering, provide the following information: Your name, title, company or organization (if applicable), address, phone number, and e-mail address. There is no fee to register for the public workshop and because seating is limited, registration will be on a first-come, first-served basis. A 1-hour lunch break is scheduled; however no food will be provided. There are multiple restaurants within walking distance of the hotel where attendees can purchase lunch. If you need special accommodations due to a disability, please contact Brookings' event coordinator at 202–797–4391 or by e-mail: *sentinelevent@brookings.edu* at least 7 days in advance.

**Transcripts:** Please be advised that as soon as a transcript is available, it will be accessible at <http://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149341.htm>. It may be viewed at the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD. A transcript will also be available in either hardcopy or on CD-ROM, after submission of a Freedom of Information request. Written requests are to be sent to the Division of Freedom of Information (HFI–35), Office of Management Programs, Food and Drug Administration, 5600 Fishers Lane, rm. 6–30, Rockville, MD 20857.

Dated: December 23, 2009.

**David Horowitz,**

*Assistant Commissioner for Policy.*

[FR Doc. E9–30971 Filed 12–29–09; 8:45 am]

**BILLING CODE 4160–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the National Advisory Allergy and Infectious Diseases Council.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Advisory Allergy and Infectious Diseases Council.

**Date:** February 1, 2010.

**Open:** 10:30 a.m. to 11:40 a.m.

**Agenda:** Report from the Institute Director.

**Place:** National Institutes of Health, Natcher Building, 45 Center Drive, Conference Rooms E1/E2, Bethesda, MD 20892.

**Closed:** 11:40 a.m. to 12:40 p.m.

**Agenda:** To review and evaluate grant applications and/or proposals.

**Place:** National Institutes of Health, Natcher Building, 45 Center Drive, Conference Rooms E1/E2, Bethesda, MD 20892.

**Contact Person:** Marvin R. Kalt, PhD, Director, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7610, Bethesda, MD